| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-016-3578-Z |
| P698 | PubMed publication ID | 27900519 |
| P50 | author | Josef Fritz | Q85636990 |
| Christian Uprimny | Q88253695 | ||
| Clemens Decristoforo | Q39559555 | ||
| Elisabeth von Guggenberg | Q56561818 | ||
| P2093 | author name string | Jasmin Bektic | |
| Wolfgang Horninger | |||
| Boris Warwitz | |||
| Irene Johanna Virgolini | |||
| Dorota Kendler | |||
| Alexander Stephan Kroiss | |||
| Llanos Geraldo Roig | |||
| Lorenza Scarpa | |||
| P2860 | cites work | The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary | Q59563285 |
| Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy | Q60606969 | ||
| Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity | Q84512331 | ||
| (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report | Q26747480 | ||
| PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data | Q31003607 | ||
| The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer | Q35043569 | ||
| Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 | ||
| Diagnosis of local recurrence after radical prostatectomy. | Q35685876 | ||
| New agents and techniques for imaging prostate cancer | Q35911784 | ||
| Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer | Q37350456 | ||
| Role of MRI in follow-up after focal therapy for prostate carcinoma | Q37757839 | ||
| The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer | Q37792304 | ||
| Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer | Q37991832 | ||
| Prostate Cancer Imaging with Novel PET Tracers. | Q38732369 | ||
| EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent | Q38939206 | ||
| EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer | Q38945683 | ||
| Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. | Q39664810 | ||
| 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer | Q39689821 | ||
| Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. | Q39710843 | ||
| A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer | Q41600550 | ||
| Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer | Q41905456 | ||
| Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. | Q46124196 | ||
| Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging | Q46339990 | ||
| Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. | Q51058133 | ||
| 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. | Q51770523 | ||
| Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. | Q52982185 | ||
| The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer. | Q52990514 | ||
| Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. | Q53023502 | ||
| Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography. | Q53031298 | ||
| Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. | Q53083003 | ||
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 | ||
| [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. | Q53176385 | ||
| (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? | Q53505313 | ||
| PET Imaging of Prostate Cancer Using Radiolabeled Choline. | Q53785189 | ||
| Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy | Q56969116 | ||
| Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP) | Q57944300 | ||
| World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects | Q58670392 | ||
| P433 | issue | 5 | |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 765-775 | |
| P577 | publication date | 2016-11-29 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions | |
| P478 | volume | 44 |
| Q55402710 | Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in 68Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma? |
| Q47794015 | Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. |
| Q57757464 | Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy |
| Q47241139 | Current status of theranostics in prostate cancer. |
| Q48316900 | Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. |
| Q63966557 | Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis |
| Q48221776 | Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T. |
| Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
| Q97886417 | Inguino-scrotal bladder hernia: an unexpected finding on 68Ga-PSMA-11 PET/CT |
| Q90366033 | Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology |
| Q57107208 | Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges |
| Q88917494 | Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11 |
| Q89747695 | Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer |
Search more.